Twenty-six studies focused on treatment of common pneumonia, of which 23 reported adverse reactions. Drug Discov. LHQW group has a reduced incidence of respiratory system damage compared to the conventional drug group (RR = 0.46, 95% CI = 0.290.74, p = 0.001). Mechanism by which ma-xing-shi-gan-tang inhibits the entry of influenza virus. However, while the potential clinical efficacy of LHQW has been demonstrated in several studies (Hu et al., 2020; Wu et al., 2020; Xiao et al., 2020; Wang et al., 2021), no consensus has been reached regarding the adverse reactions associated with LHQW therapy to date. Traditional Chinese medicine formulation used for the treatment of influenza, Uses and controversies of Lianhua Qingwen in relation to COVID-19, by region, "How traditional Chinese medicine TCM is used to treat Covid-19", "The mechanisms and clinical application of Traditional Chinese Medicine Lianhua-Qingwen capsule", "Clinical applications and pharmacological research progress of Lianhua Qingwen capsules/granules", "Traditional Chinese cures battle for acceptance in COVID-19 fight", "Chinese traditional medicine for Covid-19 becomes money tree", "Efficacy of Lianhua Qingwen Compared with Conventional Drugs in the Treatment of Common Pneumonia and COVID-19 Pneumonia: A Meta-Analysis", "Doctors warn against claims that Beijing-touted health supplement distributed in Canada treats COVID-19", "The Adverse Reactions of Lianhua Qingwen Capsule/Granule Compared With Conventional Drug in Clinical Application: A Meta-Analysis", "Beijing pushes traditional Chinese medicine as coronavirus treatment", "China Covid-19 tsar pushed treatments without revealing business ties", "Efficacy and Safety of Lianhuaqingwen Capsules, a repurposed Chinese Herb, in Patients with Coronavirus disease 2019: A multicenter, prospective, randomized controlled trial", "Prominent Chinese scientist failed to disclose company ties in COVID-19 clinical trial paper", "DOH and FDA Clarify Claims on the Approval of Potential COVID-19 Treatments and Calls for Resignation of the SoH", "Lianhua Qingwen, the FDA-approved traditional Chinese med, only treats symptoms, not COVID", "HSA Advisory on Lianhua Qingwen Products for Prevention or Treatment of COVID-19", "Fraudulent Coronavirus Disease 2019 (COVID-19) Products", "Chinese medicine Lianhua Qingwen makes its way into community for COVID-19 treatment despite Australian ban", https://en.wikipedia.org/w/index.php?title=Lianhua_Qingwen&oldid=1143380058, Short description is different from Wikidata, Articles needing expert attention from January 2023, Medicine articles needing expert attention, Articles containing simplified Chinese-language text, Articles containing traditional Chinese-language text, Articles with unsourced statements from August 2022, Creative Commons Attribution-ShareAlike License 3.0, Treatment against various respiratory diseases including, This page was last edited on 7 March 2023, at 11:01. Asia-Pacific Traditional Med. Herald. Subgroup analysis showed the incidence of dizziness or headache was significantly reduced with LHQW group (RR = 0.54, 95% CI = 0.340.84, p = 0.006), no statistical difference was detected for drowsiness and legacy neuralgia. Lianhua Qingwen has antiviral, anti-inflammatory and immunoregulatory activities. These results were different from our findings, which may be attributed to the limited number of adverse reactions reported in the previous study. Among the eight included studies on rheum therapy, six reported adverse reactions. Similar results were obtained in subgroup analysis of hepatic function abnormal and transaminase increased. 327 (7414), 557560.
Lianhua Qingwen Dosage & Drug Information | MIMS Philippines Given the small number of documents included and the low quality, the efficacy and safety of Lianhua Qingwen Capsules shall be confirmed by more high-quality clinical studies. Prof. Zhenhua Jia formulates the prescription of Lianhua Qingwen based on the theory of collateral disease, and participates in the research projects of Lianhua Qingwen against H 1 N 1 and COVID-19. Hence, the researches on specific active components of LHQW are still important and the reduction of irrelevant ingredients may be related to less adverse reactions. Mo H.Y., Ke C.W., Zheng J.P., Zhong N.S. Available at: http://www.yiling.cn/contents/75/132.html (Accessed September 14, 2021). Firstly, to our knowledge, this meta-analysis provides the most comprehensive evaluation of the clinical safety of LHQW.
Efficacy and safety of Lianhuaqingwen for mild or moderate : Medicine Immune imbalance mechanism and intervention strategy in patients with coronavirus disease 2019 (COVID-19). [11] The pro-establishment DAB alliance was found to have distributed unregistered doses of LHQW, in breach of health regulations. (Nat. The inconsistent use of conventional drugs in individual studies, along with individual differences in drug absorption, may be factors underlying high heterogeneity. (Guanghuoxiang), Rheum palmatum L. (Dahuang), Rhodiola rosea Linn. Hsieh C.F., Lo C.W., Liu C.H., Lin S., Yen H.R., Lin T.Y., Horng J.T. Second, the herbs in LHQW are mostly grown in specific areas, the varied origin of herbs are usually together with different content of bioactive ingredients, thus the quality standard control of the included crude drugs should be encouraged [12]. Available at: http://www.plantsoftheworldonline.org (Accessed December 18, 2021).
Lianhua Qingwen capsule (granule) was approved as an additional Therefore, it is essential to perform a systematic review and meta-analysis to assess the effect of Lianhua Qingwen combined with conventional antiviral Western Medicine in clinical treatment of COVID-19 or asymptomatic infection. Pharmacol. J. Pharmacovigilance. Traditional Chinese medicine, such as Lianhua Qingwen, has achieved some curative effect in many countries, but its effect is not clear. The majority of studies lacked sufficient description of allocation concealment and therefore, the project was predominantly evaluated as unclear risk of bias. Although the blinding method was not reported, since some symptom indicators needed measurement with instruments, assessment of symptom indicators was unlikely to be affected by the lack of blinding. Avoid alcohol and tobacco and spicy,cold, greasy food during taking this product. Furthermore, we also found that LHQW group has a reduced incidence of respiratory system damage compared to the conventional drug group. Declaration of competing interest. An outbreak of Coronavirus Disease 2019 (COVID-19) which was infected by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is still spreading and has led to unprecedented health emergency over the world. 12 (12), 753759754755. There was no statistically significant difference in the incidence of body as a whole-general disorders between the LHQW group and the conventional drug group (RR = 0.77, 95% CI = 0.193.01, p = 0.708). The control and improvement of the present COVID-19 situation in China could not be separated from the extensive participation of TCM, which has been proven effective by the clinical studies in COVID-19 patients [41,44,48,49]. Effect of lianhuaqingwen capsules on airway inflammation in patients with acute exacerbation of chronic obstructive pulmonary disease. Vahl. 81703740), the Zhejiang Provincial Natural Science Foundation of China (No. BMJ.
SuperHealthGuard and Loyal Great International Ltd. - 608633 - 06/26 152 (3), 393402. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement. Common side effects are heart palpitations, nausea, and vomiting. Pharmacol. Secondly, separate evaluations were further performed for different diseases and types of adverse reactions. Drafting of the manuscript was done by CH and BH. 13 (08), 676681. Notably, the stomach is full after a meal, and LHQW does not directly contact the gastric mucosa, which reduces the risk of irritation of stomach mucous membrane and thus the occurrence of side-effects. Anti Covid-19 Drugs: Need for More Clinical Evidence and Global Action. The research data were obtained from the academic databases (up to August 8, 2020) including Pubmed, CNKI and Web of Science, on ethnobotany and ethno medicines. No meta-regression was performed for COVID-19 pneumonia due to the limited number of studies. 'medicine using forsythia suspensa and lonicera japonica to clear illness',[1] LHQW) is a traditional Chinese medicine (TCM) formulation used for the treatment of influenza. Nevertheless, there are also potential limitations that need to be improved for future challenges. There was no statistically significant difference in the incidence of adverse reactions during treatment of viral influenza between the LHQW group and the conventional drug group (RR = 0.75, 95% CI = 0.471.21, p = 0.244). Meta-analysis and systematic review of efficacy and safety of Lianhua Qingwen in adjuvant treatment of adult pneumonia. Besides, in view of the definite effects of LHQW in preventing severe viral infections such as SARS and COVID-19 [17,44,45,49,52,53], LHQW may represent a considerable and effective strategy against unknown viral epidemics. (2020). Ding Y., Zeng L., Li R., Chen Q., Zhou B., Chen Q., Cheng P.L., Yutao W., Zheng J., Yang Z., Zhang F. The Chinese prescription Lianhua Qingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. The search keywords for screening the literature information were virus, COVID-19, or SARS-CoV-2, and Lianhua Qingwen. (japanese honeysuckle) flower 27.41 mg, gypsu .
Frontiers | The Adverse Reactions of Lianhua Qingwen Capsule/Granule The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Zhi-Hui Zhang and Wen-Cheng Zhou collected literatures and made the illustration. Lianhua Qingwen Prescription is approved for the treatment of fever, cough, and fatigue caused by light and common type of COVID-19 . LYY19H280006, No. Liu Y., Liu L., Cao M.M., Wen J., Zhou S., Jiang H., Zhang Y., Zhao R.S., Yang Y.H. School of Pharmacy, Faculty of Life Sciences, University College London, United Kingdom. J. Pharmacovigilance. 43 studies on treatment of respiratory tract infection were examined, with 29 reporting adverse reactions. Academician Yiling Wu systematically constructs the theory of collateral disease, provides theoretical guidance for the formulation of Lianhua Qingwen, and gives . Vahl [Oleaceae; Forsythiae Fructus] (255g), Lonicera japonica Thunb. [12], In April 2022, the Financial Times reported that the leading COVID-19 health official in the PRC, the famous epidemiologist and pulmonologist Zhong Nanshan - who has also been the most prominent scientific promoter of Lianhua Qingwen - had undisclosed prior investments in large stakeholdings in corporations producing Lianhua Qingwen and other treatments under question. Patients with severe cases will develop acute respiratory distress syndrome and septic shock, and eventually develop multi-organ failure and death [5]. (2010). [Saururaceae; Houttuyniae Botanical drug], Rheum palmatum L. [Polygonaceae; Rhei Radix et Rhizoma] (Peng et al., 2015). [4] Its formulation includes 13 herbs which are said to have been used for medical purposes as early as the Han dynasty. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. (Bohe), Glycyrrhiza uralensis Fisch. 28 (1), 1332. Management of adverse reactions was clearly documented in 38 studies, which reported improvement or resolution through discontinuation of medication, changes to post-meal administration, symptomatic or no treatment.
Dorking Swimming Pool Timetable,
Anthony Dion Fay Biography,
Braxton's Girlfriend On The Jamie Foxx Show,
Double Crown Female,
Articles L